Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Esperion Therapeutics Inc...

    NASDAQ: ESPR · Real-Time Price · USD
    1.17
    0.00 (0.00%)
    At close: Jun 17, 2025, 10:14 AM

    Esperion Therapeutics Statistics

    Share Statistics

    Esperion Therapeutics has 198.2M shares outstanding. The number of shares has increased by 16.1% in one year.

    Shares Outstanding

    n/a
    		 198.2M

    Shares Change (YoY)

    n/a
    		 16.1%

    Shares Change (QoQ)

    n/a
    		 0.41%

    Owned by Institutions (%)

    n/a
    		 64.68%

    Shares Floating

    n/a
    		 194.58M

    Failed to Deliver (FTD) Shares

    n/a
    		 253,129

    FTD / Avg. Volume

    n/a
    		 4.79%

    Short Selling Information

    The latest short interest is 26.34M, so 13.29% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 26.34M

    Short % of Shares Out

    n/a
    		 13.29%

    Short % of Float

    n/a
    		 13.35%

    Short Ratio (days to cover)

    n/a
    		 5.5

    Valuation Ratios

    The PE ratio is -7.96 and the forward PE ratio is -6.91. Esperion Therapeutics's PEG ratio is 0.09.

    PE Ratio

    n/a
    		 -7.96

    Forward PE

    n/a
    		 -6.91

    PS Ratio

    n/a
    		 1.24

    Forward PS

    n/a
    		 0.2

    PB Ratio

    n/a
    		 -1.06

    P/FCF Ratio

    n/a
    		 -17.18

    PEG Ratio

    n/a
    		 0.09
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Esperion Therapeutics.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 1.37, with a Debt / Equity ratio of -0.77.

    Current Ratio

    n/a
    		 1.37

    Quick Ratio

    n/a
    		 0.99

    Debt / Equity

    n/a
    		 -0.77

    Debt / EBITDA

    n/a
    		 39.32

    Debt / FCF

    n/a
    		 -12.42

    Interest Coverage

    n/a
    		 0.92

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 $1,093,138.16

    Profits Per Employee

    n/a
    		 $-170,213.82

    Employee Count

    n/a
    		 304

    Asset Turnover

    n/a
    		 0.97

    Inventory Turnover

    n/a
    		 0.73

    Taxes

    Income Tax

    n/a
    		 n/a

    Effective Tax Rate

    n/a
    		 0%

    Stock Price Statistics

    The stock price has increased by -59.23% in the last 52 weeks. The beta is 0.65, so Esperion Therapeutics's price volatility has been higher than the market average.

    Beta

    n/a
    		 0.65

    52-Week Price Change

    n/a
    		 -59.23%

    50-Day Moving Average

    n/a
    		 0.97

    200-Day Moving Average

    n/a
    		 1.76

    Relative Strength Index (RSI)

    n/a
    		 62.32

    Average Volume (20 Days)

    n/a
    		 5,286,390

    Income Statement

    In the last 12 months, Esperion Therapeutics had revenue of 332.31M and earned -51.74M in profits. Earnings per share was -0.28.

    Revenue

    n/a
    		 332.31M

    Gross Profit

    n/a
    		 263.71M

    Operating Income

    n/a
    		 54.4M

    Net Income

    n/a
    		 -51.74M

    EBITDA

    n/a
    		 7.57M

    EBIT

    n/a
    		 7.51M

    Earnings Per Share (EPS)

    n/a
    		 -0.28
    Full Income Statement

    Balance Sheet

    The company has 144.76M in cash and 297.6M in debt, giving a net cash position of -152.84M.

    Cash & Cash Equivalents

    n/a
    		 144.76M

    Total Debt

    n/a
    		 297.6M

    Net Cash

    n/a
    		 -152.84M

    Retained Earnings

    n/a
    		 -1.6B

    Total Assets

    n/a
    		 324.03M

    Working Capital

    n/a
    		 47.81M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -23.65M and capital expenditures -317K, giving a free cash flow of -23.97M.

    Operating Cash Flow

    n/a
    		 -23.65M

    Capital Expenditures

    n/a
    		 -317K

    Free Cash Flow

    n/a
    		 -23.97M

    FCF Per Share

    n/a
    		 -0.13
    Full Cash Flow Statement

    Margins

    Gross margin is 79.36%, with operating and profit margins of 16.37% and -15.57%.

    Gross Margin

    n/a
    		 79.36%

    Operating Margin

    n/a
    		 16.37%

    Pretax Margin

    n/a
    		 -15.57%

    Profit Margin

    n/a
    		 -15.57%

    EBITDA Margin

    n/a
    		 2.28%

    EBIT Margin

    n/a
    		 16.37%

    FCF Margin

    n/a
    		 -7.21%

    Dividends & Yields

    ESPR does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for ESPR is $4, which is 241.9% higher than the current price. The consensus rating is "Buy".

    Price Target

    n/a
    		 $4

    Price Target Difference

    n/a
    		 241.9%

    Analyst Consensus

    n/a
    		 Buy

    Analyst Count

    n/a
    		 7
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Scores

    Altman Z-Score

    n/a
    		 -6.88

    Piotroski F-Score

    n/a
    		 2

    Add to Watchlist